blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3724197

EP3724197 - FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  04.02.2022
Database last updated on 02.11.2024
FormerExamination is in progress
Status updated on  30.04.2021
FormerRequest for examination was made
Status updated on  18.09.2020
FormerThe international publication has been made
Status updated on  21.06.2019
Formerunknown
Status updated on  01.02.2019
Most recent event   Tooltip08.02.2022New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
GlaxoSmithKline Intellectual Property Development Ltd
980 Great West Road
Brentford Middlesex TW8 9GS / GB
[2020/43]
Inventor(s)01 / DEATON, Dave Norman
1250 South Collegeville Road
Collegeville, Pennsylvania 19426 / US
02 / CADILLA, Rodolfo
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
 [2020/43]
Representative(s)Knight, Lucie Viktoria, et al
GSK
Legal & Compliance - Global Patents
79 New Oxford Street
London WC1A 1DG / GB
[N/P]
Former [2020/43]Hillier, Mark
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Application number, filing date18836628.012.12.2018
[2020/43]
WO2018IB59934
Priority number, dateUS201762598003P13.12.2017         Original published format: US 201762598003 P
[2020/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019116256
Date:20.06.2019
Language:EN
[2019/25]
Type: A1 Application with search report 
No.:EP3724197
Date:21.10.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 20.06.2019 takes the place of the publication of the European patent application.
[2020/43]
Search report(s)International search report - published on:EP20.06.2019
ClassificationIPC:C07D495/04, C07D513/04, A61K31/4365, A61P21/00, A61P11/06
[2020/43]
CPC:
C07D495/04 (EP,US); C07D513/04 (EP,US); A61P11/06 (EP);
A61P21/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/43]
TitleGerman:KONDENSIERTE PYRIDINE ALS INHIBITOREN VON H-PGDS[2020/43]
English:FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS[2020/43]
French:PYRIDINES FUSIONNÉES AGISSANT EN TANT QU'INHIBITEURS DE H-PGDS[2020/43]
Entry into regional phase11.06.2020National basic fee paid 
11.06.2020Designation fee(s) paid 
11.06.2020Examination fee paid 
Examination procedure11.06.2020Amendment by applicant (claims and/or description)
11.06.2020Examination requested  [2020/43]
11.06.2020Date on which the examining division has become responsible
30.04.2021Despatch of a communication from the examining division (Time limit: M04)
11.09.2021Application deemed to be withdrawn, date of legal effect  [2022/10]
02.11.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2022/10]
Fees paidRenewal fee
09.12.2020Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.12.202104   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[E]WO2018229629  (GLAXOSMITHKLINE IP DEV LTD [GB]) [E] 1-20 * claims 1,10 *;
 [A]WO2017103851  (ASTEX THERAPEUTICS LTD [GB], et al) [A] 1-20 * claims 1,17 *;
 [A]WO2004099204  (ASTRAZENECA AB [SE], et al) [A] 1-20 * claims 1,8 *;
 [A]EP0560348  (MITSUBISHI CHEM IND [JP]) [A] 1-20 * claim 1 *
 [AD]  - WEBER J E ET AL, "Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D"2 synthase", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 45, no. 2, ISSN 0223-5234, (20100201), pages 447 - 454, (20091023), XP026835666 [AD] 1-20 * the whole document *
by applicantWO2005094805
 WO2007007778
 WO2007041634
 WO2008121670
 WO2008122787
 WO2009153720
 WO2009153721
 WO2010033977
 WO2011043359
 WO2011044307
 WO2011090062
 JP2007051121
 US2008146569
 US6576265
    - LEWIS et al., "Prostaglandin D generation after activation of rat and human mast cells with anti-lgE", J. Immunol., (19820000), vol. 129, pages 1627 - 1631
    - BOIE et al., "Molecular cloning and characterization of the human prostanoid DP receptor", J. Biol. Chem., (19950000), vol. 270, doi:doi:10.1074/jbc.270.32.18910, pages 18910 - 18916, XP002230274

DOI:   http://dx.doi.org/10.1074/jbc.270.32.18910
    - ABE et al., "Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemo-attractant receptor family", Gene, (19990000), vol. 227, pages 71 - 77
    - URADE et al., "Prostaglandin D synthase structure and function", Vitamins and hormones, (20000000), vol. 58, pages 89 - 120
    - NAKAGAWA et al., "A prostaglandin D metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old", Clinica Chimica Acta, (20130000), vol. 423, pages 10 - 14
    - MOHRI et al., "Inhibition of prostaglandin D synthase suppresses muscular necrosis", Am. J. Pathol., (20090000), vol. 174, doi:doi:10.2353/ajpath.2009.080709, pages 1735 - 1744, XP008166859

DOI:   http://dx.doi.org/10.2353/ajpath.2009.080709
    - OKINAGA et al., "Induction of hematopoietic prostaglandin D synthase in hyalinated necrotic muscle fibers: its implication in grouped necrosis", Acta Neuropathologica, (20020000), vol. 104, doi:doi:10.1007/s00401-002-0567-z, pages 377 - 84, XP008166878

DOI:   http://dx.doi.org/10.1007/s00401-002-0567-z
    - REDENSEK et al., "Expression and detrimental role of hematopoietic prostaglandin D synthase in spinal cord contusion injury", Glia, (20110000), vol. 59, pages 603 - 614
    - MOHRI et al., "Prostaglandin D -mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher", J. Neurosci., (20060000), vol. 26, pages 4383 - 4393
    - IKUKO et al., "Hematopoietic prostaglandin D synthase and DPi receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease", J. Neuropath. Exp. Neur., (20070000), vol. 66, pages 469 - 480
    - TANAKA et al., "Mast cells function as an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin J", Am. J. Physiol. Cell Physiol., (20110000), vol. 301, pages C1360 - C1367
    - PAPALIODIS et al., "Niacin-induced ''flush'' involves release of prostaglandin D from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model", JPET, (20080000), vol. 327, pages 665 - 672
    - WEBER et al., "Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D synthase", Eur. J. Med. Chem., (20100000), vol. 45, pages 447 - 454, XP026835666
    - CARRON et al., "Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (H-PGDS", ACS Med. Chem. Lett., (20100000), vol. 1, doi:doi:10.1021/ml900025z, pages 59 - 63, XP055508740

DOI:   http://dx.doi.org/10.1021/ml900025z
    - CHRIST et al., "Development and Characterization of New Inhibitors of the Human and Mouse Hematopoietic Prostaglandin D Synthases", J. Med. Chem., (20100000), vol. 53, doi:doi:10.1021/jm100194a, pages 5536 - 5548, XP055002058

DOI:   http://dx.doi.org/10.1021/jm100194a
    - HOHWY et al., "Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design", J. Med. Chem., (20080000), vol. 51, doi:doi:10.1021/jm701509k, pages 2178 - 2186, XP008145992

DOI:   http://dx.doi.org/10.1021/jm701509k
    - TURNER; BADYLACK, Cell Tissue Res, (20120000), vol. 347, no. 3, pages 759 - 74
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.